2. Search Result
Search Result
Results for "

ionotropic glutamate receptors

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

6

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2309
    Kainic acid
    Maximum Cited Publications
    35 Publications Verification

    		 EAAT Neurological Disease
    Kainic acid is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid induces seizures .
    Kainic acid
  • HY-14608
    L-Glutamic acid
    10+ Cited Publications

    		 Environmental Pollutants Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors .
    L-Glutamic acid
  • HY-14608A
    L-Glutamic acid monosodium salt
    10+ Cited Publications

    		 Environmental Pollutants iGluR Apoptosis Ferroptosis Endogenous Metabolite Neurological Disease
    L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases. L-Glutamic acid monosodium salt acts at ionotropic and metabotropic glutamate receptors .
    L-Glutamic acid monosodium salt
  • HY-N5134
    5'-Guanylic acid
    2 Publications Verification

    5'-GMP; 5'-guanosine monophosphate

    		 Endogenous Metabolite iGluR Neurological Disease Metabolic Disease
    5'-Guanylic acid is a purine nucleotide that participates in physiological processes such as energy metabolism, signal transduction, and gene expression regulation. 5'-Guanylic acid regulates the expression of genes related to fatty acid metabolism. 5'-Guanylic acid is the weak agonist for ionotropic glutamate receptors (iGluR), reduces the activity of the glutamatergic system and exhibits neuroprotective effect. 5'-Guanylic acid also causes neuronal cell death at high concentrations .
    5'-Guanylic acid
  • HY-W010970
    5'-Guanylic acid disodium salt
    2 Publications Verification

    5'-GMP disodium salt; 5'-guanosine monophosphate disodium salt

    		 Endogenous Metabolite iGluR Neurological Disease Metabolic Disease
    5'-Guanylic acid disodium salt is the disodium salt form of 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid disodium salt is a purine nucleotide that participates in physiological processes such as energy metabolism, signal transduction, and gene expression regulation. 5'-Guanylic acid disodium salt regulates the expression of genes related to fatty acid metabolism. 5'-Guanylic acid disodium salt is the weak agonist for ionotropic glutamate receptors (iGluR), reduces the activity of the glutamatergic system and exhibits neuroprotective effect. 5'-Guanylic acid disodium salt also causes neuronal cell death at high concentrations .
    5'-Guanylic acid disodium salt
  • HY-N2309A
    Kainic acid hydrate
    Maximum Cited Publications
    35 Publications Verification

    		 mGluR Neurological Disease
    Kainic acid hydrate is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid hydrate induces seizures .
    Kainic acid hydrate
  • HY-101165
    Cyclothiazide
    2 Publications Verification

    		 iGluR GABA Receptor Neurological Disease
    Cyclothiazide is a positive allosteric modulator of ionotropic AMPA-type glutamate receptors. Cyclothiazide inhibits GABAA receptors. Cyclothiazide is frequently used to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current. Cyclothiazide can potentiate responses to kainate in hippocampal neurons. Cyclothiazide has effects on glutamatergic neurotransmission. Cyclothiazide also induces epileptiform EEG activity accompanying behavioral seizures .
    Cyclothiazide
  • HY-W419700
    L-Glutamic acid ammonium
    10+ Cited Publications

    		 Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid ammonium is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid ammonium has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid ammonium acts at ionotropic and?metabotropic glutamate receptors .
    L-Glutamic acid ammonium
  • HY-W016145
    L-Glutamic acid monosodium hydrate

    		Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    L-Glutamic acid monosodium hydrate is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium hydrate has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium hydrate can be used in the study of neurological diseases. L-Glutamic acid monosodium hydrate acts at ionotropic and?metabotropic glutamate receptors .
    L-Glutamic acid monosodium hydrate
  • HY-103565
    AMN082
    1 Publications Verification

    		 mGluR Neurological Disease
    AMN082, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .
    AMN082
  • HY-N5134R
    5'-Guanylic acid (Standard)

    5'-GMP (Standard); 5'-guanosine monophosphate (Standard)

    		 Reference Standards Endogenous Metabolite
    5'-Guanylic acid is a purine nucleotide that participates in physiological processes such as energy metabolism, signal transduction, and gene expression regulation. 5'-Guanylic acid regulates the expression of genes related to fatty acid metabolism. 5'-Guanylic acid is the weak agonist for ionotropic glutamate receptors (iGluR), reduces the activity of the glutamatergic system and exhibits neuroprotective effect. 5'-Guanylic acid also causes neuronal cell death at high concentrations .
    5'-Guanylic acid (Standard)
  • HY-16713A
    (S)-(-)-5-Fluorowillardiine (hydrochloride)

    (5S)-Fluorowillardiine hydrochloride; (S)-5-Fluorowillardiine hydrochloride

    		 iGluR Neurological Disease
    (S)-(-)-5-Fluorowillardiine ((5S)-Fluorowillardiine; (S)-5-Fluorowillardiine) hydrochloride is a potent, highly selective non-NMDA ionotropic glutamate receptor (iGluR, AMPA/Kainate receptor) agonist . (S)-(-)-5-Fluorowillardiine hydrochloride activates high-affinity AMPA-preferring receptors (EC50 = 0.70 μM) and low-affinity kainate-preferring receptors (EC50 = 170 μM), thereby inducing biphasic dose-dependent neurotoxicity/excitotoxicity. (S)-(-)-5-Fluorowillardiine hydrochloride is applicable to research related to schizophrenia, temporal lobe epilepsy, and bipolar disorder .
    (S)-(-)-5-Fluorowillardiine (hydrochloride)
  • HY-101311
    UPF-523

    AIDA

    		 mGluR Inflammation/Immunology Cancer
    UPF-523 (AIDA), a rigid (carboxyphenyl) glycine derivative, is a relatively potent and selective antagonist of group I metabotropic glutamate receptors (mGlu1a) with an IC50 of 214 μM. But UPF-523 has no effect on group II (mGlu2), group III (mGlu4) receptors or ionotropic glutamate receptors. UPF-523 has the potential for the research of the acute arthritis .
    UPF-523
  • HY-100547
    IEM-1754

    		iGluR Neurological Disease
    IEM-1754, a dicationic adamantane derivative, is a potent blocker of open channels of native ionotropic glutamate receptors including quisqualate-sensitive receptors in insect muscles, NMDAR in cultured rat cortical neurons, and AMPAR in freshly isolated hippocampal cells. IEM-1754 shows anticonvulsant potency in vivo .
    IEM-1754
  • HY-101227
    (±)-threo-3-Methylglutamic acid

    		EAAT Metabolic Disease
    (±)-threo-3-Methylglutamic acid is a potent EAAT2/4 inhibitor. (±)-threo-3-Methylglutamic acid also is an ionotropic glutamate receptor agonist. (±)-threo-3-Methylglutamic acid inhibits glutamate uptake by rod outer segments .
    (±)-threo-3-Methylglutamic acid
  • HY-103565A
    AMN082 free base
    1 Publications Verification

    		 mGluR Neurological Disease
    AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .
    AMN082 free base
  • HY-103551A
    LY 541850

    		mGluR Neurological Disease
    LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells. LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively .
    LY 541850
  • HY-W016145S
    L-Glutamic acid-13C5 hydrate salt

    		Isotope-Labeled Compounds Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    L-Glutamic acid- 13C5 hydrate salt is the 13C labeled L-Glutamic acid hydrate salt. L-Glutamic acid monosodium hydrate is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium hydrate has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium hydrate can be used in the study of neurological diseases. L-Glutamic acid monosodium hydrate acts at ionotropic and?metabotropic glutamate receptors.
    L-Glutamic acid-13C5 hydrate salt
  • HY-169871
    Argiotoxin 636

    		iGluR Neurological Disease
    Argiotoxin 636 is a toxin and the non-specific, non-competitive, and potent ionotropic glutamate receptor (iGluR) antagonist. Argiotoxin 636 blocks excitatory synaptic transmission in neurons and has paralysis and muscle relaxation effects. Argiotoxin 636 can be used in the study of nervous system diseases .
    Argiotoxin 636
  • HY-101165R
    Cyclothiazide (Standard)

    		Reference Standards iGluR GABA Receptor Neurological Disease
    Cyclothiazide (Standard) is the analytical standard of Cyclothiazide. This product is intended for research and analytical applications. Cyclothiazide is a positive allosteric modulator of ionotropic AMPA-type glutamate receptors. Cyclothiazide inhibits GABAA receptors. Cyclothiazide is frequently used to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current. Cyclothiazide can potentiate responses to kainate in hippocampal neurons. Cyclothiazide has effects on glutamatergic neurotransmission. Cyclothiazide also induces epileptiform EEG activity accompanying behavioral seizures .
    Cyclothiazide (Standard)
  • HY-16713
    (S)-(-)-5-Fluorowillardiine

    (5S)-Fluorowillardiine; (S)-5-Fluorowillardiine

    		 iGluR Neurological Disease
    (S)-(-)-5-Fluorowillardiine ((5S)-Fluorowillardiine; (S)-5-Fluorowillardiine) is a potent, highly selective non-NMDA ionotropic glutamate receptor (iGluR, AMPA/Kainate receptor) agonist . (S)-(-)-5-Fluorowillardiine activates high-affinity AMPA-preferring receptors (EC50 = 0.70 μM) and low-affinity kainate-preferring receptors (EC50 = 170 μM), thereby inducing biphasic dose-dependent neurotoxicity/excitotoxicity. (S)-(-)-5-Fluorowillardiine is applicable to research related to schizophrenia, temporal lobe epilepsy, and bipolar disorder .
    (S)-(-)-5-Fluorowillardiine
  • HY-103565R
    AMN082 (Standard)

    		Reference Standards mGluR Neurological Disease
    AMN082 (Standard) is the analytical standard of AMN082. This product is intended for research and analytical applications. AMN082, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .
    AMN082 (Standard)
  • HY-103565AR
    AMN082 free base (Standard)

    		Reference Standards mGluR Neurological Disease
    AMN082 (free base) (Standard) is the analytical standard of AMN082 (free base). This product is intended for research and analytical applications. AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .
    AMN082 free base (Standard)
  • HY-119781
    Kaitocephalin

    PF1191

    		 iGluR Neurological Disease
    Kaitocephalin (PF1191) is an ionotropic glutamate receptor (NMDAR) antagonist with Ki values of 7.8, 590, and 14000 nM for NMDAR, AMPAR, and KAR, respectively. Kaitocephalin protects neurons by inhibiting excitotoxicity, exhibiting neuroprotective effects. Kaitocephalin can be used in research on neurological diseases such as Alzheimer's disease .
    Kaitocephalin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: